CA3215236A1 - Methode de traitement du cancer du poumon et du cancer du poumon non a petites cellules - Google Patents

Methode de traitement du cancer du poumon et du cancer du poumon non a petites cellules Download PDF

Info

Publication number
CA3215236A1
CA3215236A1 CA3215236A CA3215236A CA3215236A1 CA 3215236 A1 CA3215236 A1 CA 3215236A1 CA 3215236 A CA3215236 A CA 3215236A CA 3215236 A CA3215236 A CA 3215236A CA 3215236 A1 CA3215236 A1 CA 3215236A1
Authority
CA
Canada
Prior art keywords
nsclc
cancer
day
lung cancer
acylfulvene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3215236A
Other languages
English (en)
Inventor
Aditya Kulkarni
Kishor Bhatia
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lantern Pharma Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA3215236A1 publication Critical patent/CA3215236A1/fr
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5169—Proteins, e.g. albumin, gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Physics & Mathematics (AREA)
  • Inorganic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)

Abstract

L'invention concerne une méthode de traitement du cancer du poumon non à petites cellules (CPNPC) ou du cancer du poumon chez un individu, comprenant l'administration à l'individu d'une quantité efficace d'une composition comprenant des particules puissantes nanomolaires contenant de l'acylfulvène. Le traitement peut s'appliquer en fonction d'un état de cancer épidermoïde chez l'individu.
CA3215236A 2021-04-12 2022-04-12 Methode de traitement du cancer du poumon et du cancer du poumon non a petites cellules Pending CA3215236A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163173968P 2021-04-12 2021-04-12
US63/173,968 2021-04-12
PCT/US2022/071676 WO2022221834A2 (fr) 2021-04-12 2022-04-12 Méthode de traitement du cancer du poumon et du cancer du poumon non à petites cellules

Publications (1)

Publication Number Publication Date
CA3215236A1 true CA3215236A1 (fr) 2022-10-20

Family

ID=83640024

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3215236A Pending CA3215236A1 (fr) 2021-04-12 2022-04-12 Methode de traitement du cancer du poumon et du cancer du poumon non a petites cellules

Country Status (7)

Country Link
JP (1) JP2024513966A (fr)
KR (1) KR20230170695A (fr)
CN (1) CN117677601A (fr)
AU (1) AU2022256540A1 (fr)
CA (1) CA3215236A1 (fr)
MX (1) MX2023011956A (fr)
WO (1) WO2022221834A2 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2022393328A1 (en) * 2021-11-18 2024-07-04 Lantern Pharma Inc. Method for treating cancer with acylfulvene and radiation
GB2630774A (en) * 2023-06-07 2024-12-11 Curenetics Ltd Lung cancer biomarkers
CN118755828B (zh) * 2024-06-06 2025-01-14 山东大学第二医院 Hhipl2-hnrnpc信号通路在治疗非小细胞肺癌及靶向药物制备中的应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5439936A (en) * 1989-10-03 1995-08-08 The Regents Of The University Of California Method of treating certain tumors using illudin analogs
WO2007019308A2 (fr) * 2005-08-03 2007-02-15 The Regents Of The University Of California Analogues d'illudine utiles en tant qu'agents anticancereux
CN103338779B (zh) * 2011-01-11 2015-12-23 卡帝拉药物有限公司 分枝杆菌w在制备治疗癌症药物中的用途
EP3698784A1 (fr) * 2013-03-12 2020-08-26 Abraxis BioScience, LLC Procédés de traitement du cancer du poumon
US9725769B1 (en) * 2016-10-07 2017-08-08 Oncology Venture ApS Methods for predicting drug responsiveness in cancer patients
JP7489966B2 (ja) * 2018-09-04 2024-05-24 ランタン ファルマ インコーポレイテッド イルジン類似体、それらの使用、およびそれらを合成する方法
CN117797151A (zh) * 2019-03-04 2024-04-02 正大天晴药业集团股份有限公司 喹啉衍生物联合化疗药物用于治疗非小细胞肺癌

Also Published As

Publication number Publication date
CN117677601A (zh) 2024-03-08
MX2023011956A (es) 2024-01-08
JP2024513966A (ja) 2024-03-27
WO2022221834A3 (fr) 2022-11-24
AU2022256540A1 (en) 2023-11-02
KR20230170695A (ko) 2023-12-19
WO2022221834A2 (fr) 2022-10-20

Similar Documents

Publication Publication Date Title
Birzu et al. Leptomeningeal spread in glioblastoma: diagnostic and therapeutic challenges
CA3215236A1 (fr) Methode de traitement du cancer du poumon et du cancer du poumon non a petites cellules
BRPI0606839B1 (pt) Uso de uma composição farmacêutica compreendendo um inibidor irreversível de receptor de fator de crescimento epidérmico (egfr)
KR20050037510A (ko) 키나제 억제제를 사용하는 암 치료 방법
Jovanovich et al. Pediatric diffuse midline glioma: Understanding the mechanisms and assessing the next generation of personalized therapeutics
Gao et al. Combination treatment with cisplatin, paclitaxel and olaparib has synergistic and dose reduction potential in ovarian cancer cells
JP2010508277A (ja) 癌を検出および抑制するための方法
Piegeler et al. Anesthesia and colorectal cancer–the perioperative period as a window of opportunity?
EP4346998A1 (fr) Compositions et méthodes de traitement avec une association de champs électriques alternatifs et de trastuzumab
US20230181499A1 (en) Hydroxyureamethyl-Acylfulvene for Treating Brain Cancer or CNS Cancer
TWI842966B (zh) 一種具緩解抗癌藥物抗藥性及增加抗癌藥物敏感性之醫藥組合物及其用途
Ge et al. Therapeutic and preventive effects of an epidermal growth factor receptor inhibitor on oral squamous cell carcinoma
WO2022150851A2 (fr) Traitement de métastases cérébrales et de métastases du système nerveux central à l&#39;aide d&#39;illudines ou d&#39;hydroxyluréeméthyl acylfulvène
Deng et al. Clinical observation of crizotinib in the treatment of ALK-positive advanced non-small cell lung cancer
WO2011133826A2 (fr) Méthode de traitement du cancer du pancréas
BR112020016073A2 (pt) Métodos e terapia de combinação para tratar câncer do trato biliar
Bi et al. Lung squamous cell carcinoma with rare epidermal growth factor receptor mutation G719X: a case report and literature review
CN113713111A (zh) 一种治疗小细胞肺癌及克服其化疗耐药的药物组合
CN110468199B (zh) Larp7基因在癌症诊断和治疗中的应用
Yokoyama et al. Pulmonary adenocarcinoma, harboring both an EGFR mutation and ALK rearrangement, presenting a stable disease to erlotinib and a partial response to alectinib
Sequist et al. LUX-Lung 3: a randomized, open-label, phase III study of afatinib vs pemetrexed and cisplatin as first-line treatment for patients with advanced adenocarcinoma of the lung harboring EGFR-activating mutations (subgroup analysis)
US20230404908A1 (en) Compositions And Methods For Treating With A Combination Of Alternating Electric Fields And Trastuzumab
Wang et al. Multidrug resistance in the standardized treatment of colon cancer harboring a rare fibrosarcoma B-type (BRAF) p. N581I mutation: a case report
Cai Efficacy and Safety of Pemetrexed Combined with Carboplatin in The Treatment Of EGFR-Mutant Advanced NSCLC Patients After First-Line EGFR-TKI Failure
Jovanovich et al. Neuro-Oncology Advances

Legal Events

Date Code Title Description
MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD

Year of fee payment: 2

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241002

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241002

P22 Classification modified

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P22-P110 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CLASSIFICATION MODIFIED

Effective date: 20250709

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250929

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20251013

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20251014

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20251209

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED

Effective date: 20260413

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT

Effective date: 20260413

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20260413

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20260416

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT

Effective date: 20260416

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20260416

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20260416

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20260416

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260416